Provista Diagnostics Laboratory Receives Accreditation from College of American Pathologists (CAP)

New York, NY – June 26, 2014 – Provista Diagnostics, Inc., a molecular diagnostics company delivering precision medicine to the medical community to fundamentally change the detection and management of women's cancers, today announced that its CLIA-certified laboratory in Scottsdale, AZ has received accreditation from the College of American Pathologists (CAP). Accreditation was awarded following a recent on-site inspection and is designed to ensure the highest standard of care for all laboratory patients.

"Provista is committed to excellence in all that we do, and receiving CAP accreditation for our laboratory is a hallmark of how we are building our organization," said David Reese, PhD, President and CEO. "For development of our own proprietary diagnostics, as well as our work developing companion diagnostics for other companies, CAP accreditation signifies additional assurance that our lab operates under the highest quality standards to generate highly accurate and reliable results."

The College of American Pathologists (CAP) is the world's largest association composed exclusively of board-certified pathologists and is regarded as a leader in laboratory quality assurance. During the CAP accreditation process, inspectors examine the laboratory's quality and analytical procedures and processes governing patient sample testing and test reports for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management. The U.S. federal government recognizes the CAP Laboratory Accreditation Program as being equal to, or more stringent than, the government's own inspection program.

"Within the molecular diagnostics community, it is widely recognized that CAP accreditation is a difficult certification to achieve. This distinction reflects high quality standards for our lab and a tribute to the hard work and dedication of our team." said Sherri Borman, PhD, HCLD, Vice President of Laboratory Operations and Laboratory Director.

About Provista

Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at ProvistaDx.com

Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

###